Literature DB >> 15830178

Clinical significance of the physicochemical properties of LDL in type 2 diabetes.

P G Scheffer1, T Teerlink, R J Heine.   

Abstract

Atherosclerosis is the leading cause of death in type 2 diabetes. LDL cholesterol and atherosclerosis are related, both in healthy people and those with diabetes; however, people with diabetes are more prone to atheroma, even though their LDL cholesterol levels are similar to those in their non-diabetic peers. This is because LDL particles are modified in the presence of diabetes to become more atherogenic. These modifications include glycation in response to high plasma glucose levels; oxidative reactions mediated by increased oxidative stress; and transfer of cholesterol ester, which makes the particles smaller and denser. The latter modification is strongly associated with hypertriglyceridaemia. Oxidatively and non-oxidatively modified LDL is involved in plaque formation, and may thus contribute to the accelerated atherosclerosis. This review discusses the techniques currently used to determine the physicochemical properties of LDL, and examines the evidence that modification of these properties plays a role in the accelerated atherosclerosis associated with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15830178     DOI: 10.1007/s00125-005-1736-0

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  87 in total

Review 1.  Radicals and oxidative stress in diabetes.

Authors:  I C West
Journal:  Diabet Med       Date:  2000-03       Impact factor: 4.359

2.  Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men.

Authors:  K Wallenfeldt; B Fagerberg; J Wikstrand; J Hulthe
Journal:  J Intern Med       Date:  2004-11       Impact factor: 8.989

3.  Preferred orientations of LDL in vitreous ice indicate a discoid shape of the lipoprotein particle.

Authors:  Rik van Antwerpen
Journal:  Arch Biochem Biophys       Date:  2004-12-01       Impact factor: 4.013

4.  Measurement of low-density lipoprotein particle size by high-performance gel-filtration chromatography.

Authors:  P G Scheffer; S J Bakker; R J Heine; T Teerlink
Journal:  Clin Chem       Date:  1997-10       Impact factor: 8.327

5.  Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B.

Authors:  A Chait; R L Brazg; D L Tribble; R M Krauss
Journal:  Am J Med       Date:  1993-04       Impact factor: 4.965

6.  The total apolipoprotein B/LDL-cholesterol ratio dose not predict LDL particle size.

Authors:  G A Tallis; M D Shephard; S Sobecki; M J Whiting
Journal:  Clin Chim Acta       Date:  1995-08-31       Impact factor: 3.786

7.  Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles.

Authors:  Kosei Tanaga; Hideaki Bujo; Masahiro Inoue; Keiji Mikami; Kazuo Kotani; Kazuo Takahashi; Takashi Kanno; Yasushi Saito
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-04-01       Impact factor: 8.311

8.  Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient?

Authors:  A Bowie; D Owens; P Collins; A Johnson; G H Tomkin
Journal:  Atherosclerosis       Date:  1993-08       Impact factor: 5.162

9.  Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM.

Authors:  G Bellomo; E Maggi; M Poli; F G Agosta; P Bollati; G Finardi
Journal:  Diabetes       Date:  1995-01       Impact factor: 9.461

10.  The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.

Authors:  S S Soedamah-Muthu; H M Colhoun; M J Thomason; D J Betteridge; P N Durrington; G A Hitman; J H Fuller; K Julier; M I Mackness; H A W Neil
Journal:  Atherosclerosis       Date:  2003-04       Impact factor: 5.162

View more
  4 in total

1.  Serum oxidized-LDL is associated with diabetes duration independent of maintaining optimized levels of LDL-cholesterol.

Authors:  Manouchehr Nakhjavani; Omid Khalilzadeh; Leila Khajeali; Alireza Esteghamati; Afsaneh Morteza; Arsia Jamali; Sheida Dadkhahipour
Journal:  Lipids       Date:  2010-03-12       Impact factor: 1.880

2.  A novel truncated form of apolipoprotein A-I transported by dense LDL is increased in diabetic patients.

Authors:  Judit Cubedo; Teresa Padró; Maisa García-Arguinzonis; Gemma Vilahur; Inka Miñambres; Jose María Pou; Juan Ybarra; Lina Badimon
Journal:  J Lipid Res       Date:  2015-07-13       Impact factor: 5.922

3.  Coronary artery disease in patients with cystic fibrosis - A case series and review of the literature.

Authors:  Zahrae Sandouk; Noura Nachawi; Richard Simon; Jennifer Wyckoff; Melissa S Putman; Sarah Kiel; Sarah Soltman; Antoinette Moran; Amir Moheet
Journal:  J Clin Transl Endocrinol       Date:  2022-10-05

4.  Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein.

Authors:  S Lally; C Y Tan; D Owens; G H Tomkin
Journal:  Diabetologia       Date:  2006-03-04       Impact factor: 10.122

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.